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Vibrational spectroscopy of liquid biopsies
for prostate cancer diagnosis
Dinesh K. R. Medipally , Daniel Cullen, Valérie Untereiner, Ganesh D. Sockalingum,
Adrian Maguire, Thi Nguyet Que Nguyen, Jane Bryant, Emma Noone, Shirley Bradshaw,
Marie Finn, Mary Dunne, Aoife M. Shannon, John Armstrong, Aidan D. Meade*
and Fiona M Lyng*

Abstract
Background: Screening for prostate cancer with prostate specific antigen and digital rectal
examination allows early diagnosis of prostate malignancy but has been associated with
poor sensitivity and specificity. There is also a considerable risk of over-diagnosis and overtreatment, which highlights the need for better tools for diagnosis of prostate cancer. This
study investigates the potential of high throughput Raman and Fourier Transform Infrared
(FTIR) spectroscopy of liquid biopsies for rapid and accurate diagnosis of prostate cancer.
Methods: Blood samples (plasma and lymphocytes) were obtained from healthy control
subjects and prostate cancer patients. FTIR and Raman spectra were recorded from plasma
samples, while Raman spectra were recorded from the lymphocytes. The acquired spectral
data was analysed with various multivariate statistical methods, principal component analysis
(PCA), partial least squares discriminant analysis (PLS-DA) and classical least squares (CLS)
fitting analysis.
Results: Discrimination was observed between the infrared and Raman spectra of plasma and
lymphocytes from healthy donors and prostate cancer patients using PCA. In addition, plasma
and lymphocytes displayed differentiating signatures in patients exhibiting different Gleason
scores. A PLS-DA model was able to discriminate these groups with sensitivity and specificity
rates ranging from 90% to 99%. CLS fitting analysis identified key analytes that are involved in
the development and progression of prostate cancer.
Conclusions: This technology may have potential as an alternative first stage diagnostic triage
for prostate cancer. This technology can be easily adaptable to many other bodily fluids and
could be useful for translation of liquid biopsy-based diagnostics into the clinic.
Keywords: FTIR spectroscopy, liquid biopsy, partial least squares discriminant analysis and
classical least squares fitting analysis, principal component analysis, prostate cancer, Raman
spectroscopy
Received: 27 December 2019; revised manuscript accepted: 18 March 2020.

Introduction
Prostate cancer is the second most frequently
diagnosed cancer and the third most common
cause of death from cancer in men in western
countries.1 Prostate cancer constitutes about 11%
of all cancers and accounts for 9% of all the cancer
deaths among the male population within Europe.2
Despite the high survival rates for men with prostate cancer, it has been estimated that 1.3 million
new cases of prostate cancer and 359,000

associated deaths occurred worldwide in 2018.3
Prostate cancer is frequently diagnosed in the preliminary stages before it has begun to spread to
other parts of the body. The prostate gland is initially assessed with a prostate specific antigen
(PSA) blood test and a digital rectal examination
(DRE). The extensive use of PSA has proven controversial because of poor sensitivity and specificity
and is prone to false positives and false negatives in
men with symptoms suggestive of a possible
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Figure 1. Isolation of plasma from whole blood. Circulating cell free plasma biomarkers includes DNA,
micro RNA, extracellular vesicles, proteins and other analytes from both cancerous and non-cancerous sites
(inspired from14).
PBMC, peripheral blood mononuclear cells.

diagnosis of prostate cancer.4 The newly approved
4K score test5 and prostate health index test6 has
improved the PSA test but only one biomarker is
measured in these tests. DRE has also been typically employed to screen for prostate cancer. Even
though DRE has long been used to detect prostate
cancer, no controlled studies have shown its association with a decrease in the prostate cancer mortality rates.7 The screening for prostate cancer with
PSA and DRE has been regarded as controversial
despite the significant number of publications in
medical and scientific journals on its use.8 This
suggests the need for new biomarkers which can be
used to improve on (a) the early detection of prostate cancer, (b) overall prognosis and (c) offer
options for treatment monitoring. More recently,
several studies9 have used biofluids (liquid biopsies) such as plasma, serum and urine for the
detection of potential new biomarkers for prostate
cancer diagnostics and these may offer an option to
satisfy these clinical needs.
Liquid biopsies as a minimally invasive diagnostic
option for the detection of various cancers10 have several key advantages (less invasive, easily accessible,
repeated availability) and can be implemented in a
variety of healthcare scenarios, from being part of
routine health checks to intra-operative monitoring
of biofluids or therapeutic agents.11 Blood plasma
2

and serum are frequently used for detection of circulating biomarkers as plasma and serum can contain
cell free DNA, micro RNA, proteins, extracellular
vesicles and various analytes (Figure 1). Peripheral
blood mononuclear cells (PBMCs) are peripheral
blood cells with a round nucleus.12 In humans, lymphocytes constitute the majority of the PBMC population13 and play a key role in the immune system.
Thus, the characterization of this cell fraction is also
important to gain insights into disease status and systemic response.
Most liquid biopsy studies have focused on cell
free nucleic acids (cfNA) and circulating tumour
cells found in the blood plasma for the identification of prognostic, diagnostic and/or predictive
biomarkers in cancer. However, other components, such as circulating proteins, analytes and
exosomes are not as widely studied. Despite several approaches having been developed for detection of circulating DNA,15,16 circulating tumour
cells17,18 and exosomes19,20 from liquid biopsies of
cancer patients, these assays have not seen translation to the clinic.
Vibrational spectroscopy techniques, such as
Raman and infrared (IR) spectroscopy are nondestructive, non-invasive and reagent free, providing biochemical profiles of cells, tissues and
journals.sagepub.com/home/tam
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biofluids. IR spectroscopy is based on the absorption of IR radiation by the sample under study and
the fact that molecules absorb specific frequencies
of the incident light which are characteristic of
their structure. Raman spectroscopy is based on
inelastic scattering of monochromatic light, usually from a laser source. Inelastic scattering means
that the frequency of photons in monochromatic
light change upon interaction with a sample.21
These techniques have been applied to biofluids
(serum or plasma) for discriminating between non
cancer controls and head and neck cancer
patients,22,23 breast cancer patients,24 cervical cancer patients25 and prostate cancer patients26 with
sensitivities and specificities above 75%.
In the present study, Raman and IR spectra were
recorded from plasma samples obtained from
healthy donors and prostate cancer patients, while
Raman spectra were recorded from the lymphocytes. Significant spectral differences were observed
between the Raman and IR spectra of plasma and
lymphocyte samples from healthy donors and
prostate cancer patients. Similarly, significant
spectral differences were observed in the plasma
and lymphocytes between patients exhibiting different Gleason scores (GS). The acquired Raman
and IR spectra were also analysed by principal
component analysis (PCA), partial least squares
discriminant analysis (PLS-DA) and classical least
squares (CLS) fitting analysis to discriminate individuals with and without disease and provide
insights into the underlying molecular species providing this discrimination. The PLS-DA classifier
was able to classify the presence of disease with
sensitivities and specificities ranging from 90% to
99%. The CLS fitting analysis identified several
analytes that are involved in the development and
progression of prostate cancer.
Materials and methods
Ethical approval
Ethical approval was awarded by the Technological
University Dublin Research Ethics Committee
(REC number 15-32) for the collection of blood
samples from healthy donors. The prostate cancer patients for this study were recruited from
the Cancer Trials Ireland (formerly All Ireland
Cooperative Oncology Research Group, ICORG)
trial 08−17 which is entitled ‘A Prospective phase
II Dose Escalation Study Using intensity modulated radiotherapy (IMRT) for High Risk N0 M0

journals.sagepub.com/home/tam

Prostate Cancer (ClinicalTrials.gov identifier:
NCT00951535)’. The primary endpoint is to
determine if dose escalation up to 81 Gy using
IMRT for high risk localised prostate cancer can
provide PSA relapse-free survival similar to that
previously reported.27 A subgroup of patients were
recruited for a translational study on vibrational
spectroscopy for monitoring radiation therapy
response28 related to the present study. The translational research study was approved by the St
Luke’s Radiation Oncology Network Research
Ethics Committee and all research was performed
in accordance with relevant guidelines and regulations. Informed consent was obtained from all participants covering the donation of the blood sample
and access to the de-identified clinical data. Fresh
whole blood was drawn into Li-heparin tubes at
St. Luke`s Radiation Oncology Network in Dublin
and were coded before being transferred to the
Technological University (TU) Dublin laboratory.
For this study, a total of 43 prostate cancer patients
and 33 healthy control volunteers were recruited.
Of these cohorts, plasma samples were collected
from 37 prostate cancer patients and 33 healthy
control subjects and lymphocyte samples were collected from 29 prostate cancer patients and 26
healthy control subjects. The demographics of
healthy donors and prostate cancer patients
recruited for this study are detailed in Table 1.
Plasma isolation
Plasma was isolated from these blood samples by
centrifugation at 3500 g for 5 min at 18°C. The
samples were subsequently stored at –80°C prior
to Fourier Transform Infrared (FTIR) and Raman
acquisition.
Isolation of lymphocytes
Fresh whole blood was drawn from healthy donors
and patients into lithium-heparin tubes and
PBMCs were isolated within 24 h of collection as
described previously.29 A total of 6 ml of
Dulbecco’s modified phosphate buffered saline
(DPBS; Sigma Aldrich LLC, St Louis, MO) was
added to 6 ml of heparinised blood, mixed by gentle inversion and overlaid onto 15 ml of Histopaque
(Sigma Aldrich LLC). Samples were centrifuged
at 400 g for 30 min at room temperature. The
PBMC layer was removed using a pipette and the
rest of the contents were discarded. PBMCs were
washed by adding 10 ml of DPBS (Sigma Aldrich
LLC) and gently mixed by inversion.

3
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Table 1. Summary of subjects recruited in the study.
Prostate cancer

Healthy donors

Subjects recruited

43

33

Sex

M

M

Mean

68.26

39.6

Median

69.5

37.0

Range

57–79

23–60

Mean

17.22

Not measured

Median

9.4

Age (years)

PSA (ng/ml)

T Stage
T2a to T2c

11 (26%)

T3a

23 (53%)

T3b

08 (19%)

T4a

01 (2%)

NA

Gleason score
7

14 (33%)

8

16 (37%)

9

13 (30%)

NA

PSA, prostate specific antigen.

Samples were washed a total of three times.
Finally, cells were pelleted by centrifugation at
250 g for 5 min at room temperature. Supernatant
was discarded and the cell pellet was resuspended
in 3 ml of full media (RPMI + 12.5% (v/v)
FBS + 2 mM L-glutamine; Sigma Aldrich LLC)
supplemented with 2.5% (v/v) phytohaemagglutinin (PAA Laboratories Ltd, Somerset, UK). A
total of 1 ml of cell suspension was transferred to a
T25 flask containing 4 ml of full media. A total of
three flasks were prepared for each donor. Flasks
were placed on their side and incubated for 72 h at
37°C and 5% CO2 to allow separation of lymphocytes and monocytes by plastic adherence.
FTIR spectroscopy. The sample preparation and
acquisition methodology for FTIR spectra has
been detailed previously.28 The acquired FTIR
spectra were subjected to a quality test (OPUS
v6.5) as previously described.30,31 Spectra that
4

passed the quality test were pre-processed and
analysed in the wavenumber range from 800 cm−1
to 4000 cm−1.
Raman spectroscopy
Blood plasma. Raman spectroscopy was
performed using an in house developed high
throughput (HT)-Raman spectroscopy method32
on a Horiba Jobin Yvon Labram HR800 UV
micro-spectroscopy system (Horiba UK Ltd,
Middlesex, UK). Briefly, 20 µl of liquid plasma
was deposited on a cover glass bottomed 96 well
plate (MatTek corporation) and Raman spectra of the plasma samples were acquired using
a 785 nm laser focused through a 10× objective
(N.A. 0.25). Spectra were recorded using a diffraction grating ruled with 300 lines/mm giving
a spectral resolution of ~2.1 cm–1. Spectra were
recorded automatically from each well where the
spectrometer was programmed using an in-house
developed high throughput macro template. Each
spectrum was acquired over the region from
400 cm–1 to 1800 cm–1. Ten spectra were recorded
from each sample for each patient with a 20 s × 2
integration time. Multiple wavenumber calibration spectra of 1,4-Bis (2-methylstyryl) benzene
and intensity calibration spectra of National Institute of Standards and Technology (NIST) Standard Reference Material (SRM) no. 2241 were
recorded along with each sample acquisition and
used in spectral post-processing.
Lymphocytes. For Raman spectroscopy, cells
were fixed using 4% paraformaldehyde (AppliChem GmbH, Darmstadt, Germany) in DPBS
(Sigma Aldrich LLC). From the suspension,
40 µl was drop cast onto calcium fluoride (CaF2)
slides. The slides were then washed in deionised water and the samples were allowed to
dry. Raman spectroscopic measurements were
performed using a Horiba Jobin Yvon Labram
HR800 UV micro-spectroscopy system (Horiba UK Ltd, Middlesex, UK) equipped with a
660 nm solid-state diode laser and calibrated
using silicon.
A 100× objective (N.A. 0.95) and a diffraction
grating of 300 lines/mm (centred at 1450 cm–1)
were used. The laser intensity was set to 100%
and the confocal hole was set to 100 μm. A total
of 30 spectra were collected from each patient
sample. Spectra were recorded with a 20 s integration time and averaged over 3 integrations.
Each spectrum was recorded using a 4 × 4 µm raster scan of the centre of each cell.
journals.sagepub.com/home/tam
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Table 2. Pure molecular reference species used in the plasma study.
Category

Pure molecular reference species

Protein and related compounds

Albumin, Apolipoprotein E4, Keratin, Interleukin-1, Interleukin-6, Interleukin-8 and
Ubiquitin,

Lipids and Fatty acids

Arachidonic acid, Cholesterol, Linolenic acid, Linoleic acid, Oleic acid, Triglyceride,
PUFA, Sphingomyelin, Phosphatidylcholine, Phosphatidylethanolamine,
Phosphatidylserine, Prostaglandin E1, Phosphatidylinositol

Nucleic acids

DNA and RNA

Growth factors

Epidermal growth factor and KGF

Antioxidants and free radical scavengers

Uric acid and β-carotene,

Metabolism

Glucose, Glycogen, Creatinine

Enzymes

Carbonic anhydrase

PUFA, polyunsaturated fatty acid; KGF, keratinocyte growth factor.

Pure molecular reference species
All pure molecular reference species (Tables 2
and 3) were purchased from Sigma Aldrich in
lyophilised form. Approximately 1–2 mg of each
lyophilised analyte or 10 µl of liquid analyte was
deposited on a calcium fluoride slide and Raman
spectra were recorded with a 660 nm and 785 nm
laser excitation. The laser was focused through a
10× objective (N.A. 0.25) using a diffraction grating ruled with a grating of 300 lines per mm. Five
spectra per sample were recorded with an acquisition time of 10 s and averaged over 2 accumulations. FTIR spectra of all analytes were recorded
using an attenuated total reflectance (ATR)-FTIR
crystal (Perkin Elmer). Approximately 1 mg of
lyophilised sample or 5 µl of liquid analyte (allowed
to dry at room temperature) was placed on the
ATR crystal (diamond/zinc selenide with refractive index 2.4) and FTIR spectra were acquired in
the transmission mode using the spectrum software and using the following conditions: wavenumber range from 700 cm−1 to 4000 cm−1,
spectral resolution of 4 cm−1, and each spectrum
was averaged over 8 scans. Tables 2 and 3 shows
the list of pure molecular reference species used in
the plasma and lymphocyte study, respectively.
Data analysis
All spectral processing procedures were carried
out within MATLAB (R2017a; Mathworks Inc.,
Natick, MA), along with in-house developed
algorithms and procedures available within the
PLS Toolbox (v 8.0.2, Eigenvector Research
Inc., Wenatchee, MA).
journals.sagepub.com/home/tam

Pre-processing
Plasma FTIR spectra. Pre-processing of FTIR
spectra includes baseline correction, calculation
of second derivative spectra and vector normalisation. Baseline correction was performed using
the rubberband baseline subtraction.33 Second
derivative spectra were calculated using the Savitzky–Golay algorithm34 and a window length of
nine points. All spectra were standardised using
vector normalisation before analysis.
Plasma Raman spectra. The acquired Raman
spectra were wavenumber calibrated relative to an
in-house standard of 1,4-Bis (2-methylstyryl)
benzene using in-house developed calibration
procedures35 and the instrument response correction was performed using the spectrum of NIST
SRM no. 2241, according to the method
described.36 The wavenumber and instrument
response corrected Raman spectra were smoothed
using a Savitzky–Golay filter. Background and
baseline correction were performed using
extended multiplicative scattering correction. All
spectra were standardised using vector normalisation before analysis.
Lymphocyte Raman spectra. All spectra were
wavenumber calibrated using an in-house standard of 1,4-Bis (2-methylstyryl) benzene in conjunction with in-house developed algorithms in
Matlab v.9.3 (Mathworks Inc., Natick, MA).
Spectra from NIST SRM no. 2245 were used to
perform instrument response correction according to the method described.37 Baseline correction was performed using a rubberband baseline
5
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Table 3. Pure molecular reference species used in the lymphocyte study.
Category

Pure molecular reference species

Protein and related compounds

Actin, Histone (type 2A), Keratin, Ubiquitin, Interleukin-8, Tumour necrosis f actor-alpha,

Lipids and Fatty acids

Arachidonic acid, Cholesterol, Linolenic acid, Linoleic acid, Triglycerides, PUFA,
Phosphatidylcholine, Prostaglandin E1 (PGE1)

Nucleic acids and related compounds

DNA, RNA, Deoxyuridine and Thymidine

Other analytes

ATP, β-carotene, Glycogen, Uric acid and Cytochrome C

PUFA, polyunsaturated fatty acid.

subtraction, and all spectra were standardised
before analysis.
Multivariate analyses
Pre-processed FTIR and Raman spectra were
analysed using PCA, PLS-DA and CLS fitting
analysis. Second derivative FTIR spectra were
used for the multivariate analysis because this
allows more distinct identification of small and
adjacent lying absorption peaks which are not
clearly distinguishable in the original spectrum.
PCA. PCA was performed as described previously.28 In brief, PCA is a commonly used method
for multivariate data compression and visualization. It describes data variance by identifying a
new set of orthogonal features, called principal
components (PCs).
PLS-DA. PLS-DA is a linear classification model
based on partial least squares regression,38 where
the y variable (the regression target) is encoded as
the discrete spectral class (cancer or control).39
PLS-DA aims to obtain maximum covariance
between the independent and dependent variables of a multidimensional dataset by finding a
linear subspace. This new subspace allows the
prediction of dependent variables using a reduced
number of factors, known as latent variables
(LVs).40 The details of the PLS-DA approach
used in this study are fully described by us
previously.28
CLS fitting analysis. In this study, CLS fitting
analysis was performed on the vector normalised
second derivative FTIR spectra and vector normalised Raman spectra to estimate the relative
fraction (a proxy for concentration) of reference
spectra (of pure components) within a sample

6

spectrum. The use of CLS fitting analysis to
determine the relative concentrations of cellular
components have been reported previously.41–43
The pure components used in this study are given
in Table 2 and 3. All these pure molecular reference species are directly or indirectly related to
the development and progression of cancer. CLS
is an exploratory method that assumes that any
complex spectrum is the linear sum of contributions from spectra of pure components that contribute to the spectrum as described in the
following equation44
S = a1C1 + a2 C2 +…+ E
Where S represents a sample spectrum, a1 and a2
are component spectra and C1 and C2 are the
weights or concentrations assigned to each component spectrum. In the case of a Raman or FTIR
spectrum, not all contributing pure components
are known. Therefore, E represents the error or
residual matrix. CLS therefore aims to minimise
the squared differences between the fit and the
spectrum using a set of reference pure molecular
spectra.
Results
Spectral features: healthy donors versus
prostate cancer patients
For comparison of spectral features, a mean spectrum was computed for each class. To explain the
differences between each group, difference spectra were computed by subtracting the mean spectra of plasma from healthy donors from the mean
spectra of plasma from prostate cancer patients.
The resulting mean and difference Raman spectra of plasma from healthy donors (n = 33) and

journals.sagepub.com/home/tam
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Figure 2. Mean Raman spectra of plasma from
healthy donors and prostate cancer patients (top
panel). Difference spectrum of cancer and control
spectra (bottom panel). The shaded regions depict
the spectral regions which are significantly different
between each sample set using a two-tailed t-test
with p < 0.001.

prostate cancer patients (n = 37) are presented in
Figure 2. Statistically significant differences
(p < 0.001) were observed between the classes.
Differences in the form of intensity-related variations were observed across these mean spectra.
Major differences were observed for tyrosine
(830, 850 cm−1), DNA/RNA (940, 1085, 1340,
1420 cm−1), β-carotene (1160, 1525 cm−1), amide
linkages (1302, 1340 cm−1), CH2 deformation
(1340), tryptophan ( ̴ 1332–1363 cm−1), phenylalanine (1006 cm−1, 1210 cm−1), lipids and proteins
(622 cm−1, 644 cm−1, 1300 cm−1, 1400–1470 cm−1,
1640–1670 cm−1) in all the spectra. The tentative
band assignment of the observed spectral features
is based on the existing literature.45
The mean and difference Raman spectra of lymphocytes from healthy donors (n = 26) and prostate cancer patients (n = 29) are presented in
Figure 3. Differences in the form of intensity
related variations were observed across the mean
spectra. Decreases were observed in bands corresponding to cholesterol and C-C twisting of proteins (616–622 cm−1), C-C twisting of tyrosine
(637–644 cm−1), ring breathing modes of DNA/
RNA bases and O-P-O stretching of DNA (721–
809 cm−1), saccharides and ring breathing mode
journals.sagepub.com/home/tam

Figure 3. Mean Raman spectra of lymphocytes from
healthy donors and prostate cancer patients (top
panel). Raman difference spectrum of lymphocytes
from healthy controls and prostate cancer patients
(bottom panel). The shaded regions depict the
spectral regions which are significantly different
between each sample set using a two-tailed t-test
with p < 0.001.

of tyrosine (848–863 cm−1), carbohydrates, proline and hydroxyproline (925–941 cm−1), phenylalanine (998–1013 cm−1), DNA, lipids and
carbohydrates (1088–1113 cm−1), tyrosine, lipids
and DNA/RNA bases (1165–1191 cm−1), amide
III (1245–1279 cm−1), CH3/CH2 twisting and
bending of lipids and collagen (1310–1403 cm−1),
DNA/RNA bases and β-carotene (1460–
1525 cm−1) in prostate cancer patients when compared with healthy controls. In addition, increases
were observed in bands corresponding to the CH2
deformation of lipids (1423–1443 cm−1), guanine
and adenine (1573 cm−1), cytosine, tyrosine and
phenylalanine (1606–1612 cm−1) and tryptophan
and amide I (1618–1669 cm−1) in prostate cancer
patients when compared with healthy donors.
Figure 4 shows the vector normalised mean FTIR
spectra of plasma from healthy donors (n = 33)
and prostate cancer patients (n = 37). Differences
in the form of intensity-related variations were
observed across these mean spectra. Major differences in the regions around 1020–1040 cm−1
(C-O stretching and bending vibrations
7
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Figure 4. Mean FTIR spectra of plasma from
healthy donors and prostate cancer patients (top
panel). Difference spectrum of cancer and control
spectra (bottom panel). The shaded regions depict
the spectral regions which are significantly different
between each sample set using a two-tailed t-test
with p < 0.001.
FTIR, Fourier Transform Infrared.

of glycogen), 1070–1090 cm−1 (symmetric
stretching of PO2–, nucleic acids, phospholipids
and saccharides), 1120–1170 cm−1 [stretching
vibrations of (C-O) and ν(C-O-C) of carbohydrates], 1240 cm−1 (nucleic acids), 1300–
1400 cm−1 (amide III), 1544 cm−1 (Amide II),
1656 cm−1 (Amide 1), 1740–1760 cm−1 [stretching vibrations of (C=O) of fatty acids, triglycerides and cholesterol esters], 2800–2965 cm−1
[stretching vibrations of (CH2/CH3) of lipids,
fatty acids, triglycerides and proteins] 3300 cm−1
(Amide A), and 3400–3600 cm−1 (OH stretch of
carboxylic acids) were observed in the plasma
spectra of healthy donors and prostate cancer
patients.
Spectral features varying with Gleason score
The mean and difference Raman spectra of
plasma from prostate cancer patients with varying
GS [GS 7 (n = 10), GS 8 (n = 11), GS 9 (n = 09)]
are presented in Figure 5. Significant differences
were observed for tyrosine (830, 850 cm−1),
DNA/RNA (940, 1085, 1340 and 1588 cm−1),
phenylalanine (1007, 1210 cm−1), β-carotene
(1155 and 1525 cm−1), amide linkages (1302,
1340 cm−1), CH2 deformation (1340), tryptophan
8

Figure 5. Mean Raman spectra of plasma from
prostate cancer patients with Gleason scores (GS) 7, 8
and 9 (top panel). Difference spectra of plasma from
patients with different GS (bottom three panels). The
shaded regions depict the spectral regions which are
significantly different between each sample set using
a two-tailed t-test with p < 0.001.

(∼1332–1363 cm−1), phospholipids (1450 cm−1)
and lipids/proteins (1640–1660 cm−1) in all the
spectra. An increase in the bands related to tyrosine, tryptophan, DNA/RNA, amide linkages and
CH2 deformation and a decrease in the bands
related to phenylalanine, β-carotene, lipids and
proteins was observed with an increase in GS.
The mean and difference Raman spectra of lymphocytes from prostate cancer patients with different GS [GS 7 (n = 07), GS 8 (n = 13), GS 9
(n = 09)] are presented in Figure 6. Differences in
the form of intensity-related variations were
observed across the mean spectra. The bands corresponding to phosphodiester, saccharides and
journals.sagepub.com/home/tam
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Figure 6. Mean Raman spectra of lymphocytes from
prostate cancer patients with Gleason scores (GS) 7,
8 and 9 (top panel). GS difference spectra for Raman
lymphocyte spectra (bottom three panels). The
shaded regions depict the spectral regions which are
significantly different between each sample set using
a two-tailed t-test with p < 0.001.

deoxyribose (850–980 cm−1), phospholipids,
lipids and C-C stretching in carbohydrates (991–
1098 cm−1) and amide I and fatty acids (1649–
1666 cm−1) were increased with an increase in GS.
The bands corresponding to hydroxyproline,
tyrosine, amide III, C-C and C-N stretching
(1197–1264 cm−1), CH3CH2 wagging of nucleic
acids, CH2 twisting and wagging of lipids, triglycerides and guanine (1293–1336 cm−1), RNA/
DNA and tryptophan (1344–1420 cm−1) and
carotenoid, Amide II, tryptophan, RNA/DNA,
journals.sagepub.com/home/tam

Figure 7. Mean FTIR spectra of plasma from prostate
cancer patients with Gleason scores (GS) 7, 8 and
9 (top panel). Difference spectra of plasma from
patients with different GS (bottom three panels). The
shaded regions depict the spectral regions which are
significantly different between each sample set using
a two-tailed t-test with p < 0.001.

tyrosine and phenylalanine (1504–1626 cm−1)
were decreased with an increase in GS.
The mean and difference FTIR spectra of plasma
from prostate cancer patients with different GS
[GS 7 (n = 10), GS 8 (n = 11), GS 9 (n = 09)] are
presented in Figure 7. Differences in the form of
intensity-related variations were observed in the
regions around 1040–1080 cm−1, 1120–1170 cm−1,
1240 cm−1, 1300–1400 cm−1, 1545 cm−1, 1656 cm−1,
1738 cm−1, 2800–2963 cm−1 and 3300–3500 cm−1
9
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Figure 8. PCA for Raman spectra of plasma from
healthy donors and prostate cancer patients.
Covariance ellipse (95% confidence) are shown for
each class.
PCA, principal component analysis.

in the plasma spectra of prostate cancer patients
with different GS. The bands corresponding to
DNA/RNA (1080, 1240 cm−1), carbohydrates
(1120, 1170 cm−1), proteins (1300–1700 cm−1),
fatty acids (1740 cm−1), lipids (2800–2950 cm−1)
were increased with an increase in Gleason score
and the bands corresponding to Amide A Figure 9. PCA for Raman spectra of healthy donors
(3300 cm−1) and OH stretch (3400–3600 cm−1) and prostate cancer lymphocyte samples. (a) Score
plot (b) PC1 and PC2 loading plots. Covariance
were decreased with an increase in GS.
ellipses (95% confidence) are shown for each class.
PCA, principal component analysis.

Multivariate analyses
PCA. PCA was performed on the mean Raman
spectra of plasma from healthy donors and prostate
cancer patients using the wavenumber range of
600–1800 cm−1. The first two PCs accounted for
~53% of the total percentage variance and the scatter plot of PC 1 versus PC 2 revealed two overlapped
clusters between the two classes (Figure 8).

10

PC2 revealed two well differentiated clusters
between the classes.

Figure 9 shows the PCA performed on the mean
Raman spectra of lymphocytes from healthy
donors and prostate cancer patients using the
wavenumber range of 400–1800 cm−1. The first
two PCs accounted for 71% of the total percentage variance and the scatter plot of PC 1 versus
PC 2 revealed two minimally overlapping clusters
between the two classes.

Figure 11 shows the PCA results performed on
the mean Raman spectra of plasma and lymphocytes from prostate cancer patients with different
GS. For plasma spectra, the first two PCs
accounted for 66.7% of the total percentage variance and were used to visualise the classification
between the groups. For lymphocyte spectra,
PC1 and PC2 accounted for 56% of the total percentage variance and were used to visualise the
classification between the groups. The scatter
plot revealed overlapping clusters between the
analysed classes without any discrimination

Figure 10 shows the PCA results performed on
second derivative mean FTIR spectra using the
wavenumber range of 800-4000 cm−1. The first
two PCs accounted for ~86% of the total percentage variance and the scatter plot of PC1 versus

Figure 12 shows the PCA results performed on
second derivative mean FTIR spectra of plasma
from prostate cancer patients with different GS.
The first two PCs accounted for 75.7% of the
total percentage variance. The scatter plot of PC1
journals.sagepub.com/home/tam
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(a)

(b)
Figure 10. PCA for FTIR spectra of plasma from healthy donors and prostate cancer patients’ samples.
(a) Score plot (b) PC1 and PC2 loading plot. Covariance ellipse (95% confidence) are shown for each class.
PCA, principal component analysis.

versus PC2 revealed three well differentiated clusters between the classes.
PLS-DA. PLS-DA analysis was performed to classify plasma and lymphocyte spectra from healthy
donors and prostate cancer patients, as well as
from prostate cancer patients with different GS
based on the observed spectral features. Table 4
shows the classification sensitivities and specificities for Raman spectra and are calculated for the
cross validated PLS-DA model. Table 5 shows the
results of PLS-DA performed on the Raman
spectra of lymphocytes.
Table 6 shows the classification sensitivities and
specificities for FTIR spectra and are calculated
for the cross validated PLS-DA model.

journals.sagepub.com/home/tam

CLS fitting analysis. CLS fitting analysis was performed on the Raman spectra and second derivative FTIR spectra of plasma from healthy donors
and prostate cancer patients to identify the biochemical species that are involved in the development and progression of prostate cancer. The
reference biochemical spectra used in the plasma
study are listed in Table 2. Figure 13 shows the
results of CLS fitting analysis performed on the
Raman spectra of plasma from healthy donors
and prostate cancer patients with different GS.
An increased weighting of uric acid, interleukin-6,
phosphatidylethanolamine, creatinine and RNA
and a decreased weighting of albumin and βcarotene was observed in the Raman spectra of
plasma from prostate cancer patients compared
with the healthy donors.

11
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(a)

(b)
Figure 11. PCA scatter plot for Raman spectra from
(a) plasma and (b) lymphocytes from prostate cancer
patients with different Gleason score. Covariance
ellipse (95% confidence) are shown for each class.
PCA, principal component analysis.

Figure 14 shows the results of CLS fitting analysis
performed on the second derivative FTIR spectra
of plasma from cancer and control cohorts. A
decreased weighting of albumin, phosphatidylethanolamine, ubiquitin and increased weighting
of interleukin-6, interleukin-8, keratinocyte
growth factor (KGF), phosphatidyl-inositol,
phosphatidyl-serine, uric acid and triglyceride
was observed in the plasma from prostate cancer
patients compared with healthy donors. A
decreased weighting of albumin and increased
weighting of uric acid and interleukin-6 were also
observed in the Raman spectral analysis. Elevated
serum levels of Interleukin-8 were reported in
patients with localised disease and androgen
independent prostate cancer.46 Decreasing levels
of plasma Interleukin-8 was observed with
increasing GS.
12

Figure 15 shows the results of CLS fitting analysis performed on the Raman spectra of lymphocytes from cancer and control cohorts. The list
of pure molecular reference species used in this
study is given in Table 3. These pure molecular
reference species include cellular components
and other analytes involved in the development
and progression of cancer. The alterations in
the weighing of actin, cholesterol, RNA, interleukin-8, linoleic acid, prostaglandin E1, polyunsaturated fatty acid (PUFA), uric acid,
β-carotene, tumour necrosis factor alpha (TNFα), histone (or histone 2A), glycogen, and ubiquitin were observed between the lymphocyte
spectra of healthy donors and prostate cancer
patients with different GS.
Discussion
The mean and difference Raman spectra of
plasma from healthy donors and prostate cancer patients show significant contributions from
various biochemical components such as DNA,
amino acids, proteins, lipids and β-carotene.
The bands of the DNA backbone (940,
1085 cm−1) and nitrogenous bases (1340, 1420
and 1556 cm−1) were more intense in the mean
spectrum of prostate cancer patients when
compared with that of healthy donors. The
presence of more intense DNA bands in prostate cancer samples may indicate high levels of
cell-free DNA under cancer conditions.47 An
increased expression of cfNA such as DNA,
RNA and mRNA has been detected in the
blood circulation of cancer patients.48 This
might be due to the increased incidence of
necrosis and apoptosis, or the release of intact
cells in the bloodstream and their subsequent
lysis.48 Moreover, the changes in the levels of
cfNA have also been associated with tumour
burden and tumour progression.47 An increased
intensity in bands corresponding to amide linkages (1302, 1340 cm−1) were observed in the
spectra from prostate cancer patients relative to
healthy donors. This might be due to some proteomic perturbations such as changes in secondary structure. In addition, the bands
corresponding to CH2 deformation (1340 cm−1)
and lipids (1300, 1430–1440 cm−1) were also
found to be more intense in prostate cancer,
whereas the bands associated with proteins and
phospholipids (1450–1470, 1666 cm−1) were
more intense in healthy donors. Several studies
have reported an increase serum/plasma lipids
including phospholipids and fatty acids during
journals.sagepub.com/home/tam

DKR Medipally, D Cullen et al.

(a)

(b)
Figure 12. PCA for FTIR spectra of plasma from prostate cancer patients with different Gleason score samples.
(a) Score plot (b) PC1 and PC2 loading plot. Covariance ellipse (95% confidence) are shown for each class.
PCA, principal component analysis.

prostate cancer progression.49,50 Higher levels
of β-carotene (1160, 1525 cm−1) were observed
in the spectra of healthy donors in comparison
with prostate cancer patients. It has been previously reported that the amount of β-carotene
present in the blood decreases during cancer
conditions. Carotenoid abundance has been
shown to be depleted in the cancerous state of
several organs including breast, lung, liver and
colon51 and to contribute to the discrimination
between normal, benign and malignant breast
tissues.52 Translocation of plasma free fatty
acids to support visceral or tumour protein synthesis is an important feature observed in cancer patients. Previous studies have reported
that levels of phenylalanine, tyrosine and tryptophan may be altered in different cancers.22
journals.sagepub.com/home/tam

Amino acids as tyrosine (830, 850 cm−1) and
tryptophan (~1332–1363 cm−1) also showed
relatively higher levels in plasma from cancer
patients in comparison with plasma from
healthy donors. On the other hand, peaks for
phenylalanine (1007, 1210 cm−1) were found to
be more intense in plasma from healthy donors.
Similarly, an increase in CH2 deformation of
lipids, tryptophan, nucleobases and decrease in
β-carotene were also observed in the Raman
spectra of lymphocytes from prostate cancer
compared with the healthy donors.
FTIR spectra of plasma from healthy donors
shows high intense bands at 1080 cm−1 and
1240 cm−1 compared with plasma from cancer
patients. The two bands in this region at 1080 cm−1
13
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Table 4. Sensitivities and specificities for the PLS-DA classification of Raman spectra from plasma of healthy
donors and prostate cancer patients, as well as plasma spectra from patients with different GS.
Patients

Number of LVs

Sensitivity

Specificity

Healthy donors versus prostate
cancer patients

06

89.6%

90%

GS 9 versus GS 8

07

78.7%

80%

GS 9 versus GS 7

04

70%

75.7%

GS 8 versus GS 7

04

63.3%

66.5%

GS, Gleason score; PLS-DA, partial least squares discriminant analysis.

Table 5. Sensitivities and specificities for the PLS-DA classification of Raman spectra from lymphocytes of
healthy donors and prostate cancer patients, as well as lymphocytes spectra from patients with different GS.
Patients

Number of LVs

Sensitivity

Specificity

Healthy donors versus prostate
cancer patients

07

92%

90%

GS 9 versus GS 8

03

65%

85%

GS 9 versus GS 7

10

85%

95%

GS 8 versus GS 7

13

80%

75%

GS, Gleason score; PLS-DA, partial least squares discriminant analysis.

Table 6. Sensitivities and specificities for the PLS-DA classification of plasma FTIR spectra from healthy
donors and prostate cancer patients, as well as plasma spectra from patients with different GS.
Patients

Number of LVs

Sensitivity

Specificity

Healthy controls versus prostate
cancer patients

12

99%

98.4%

GS 9 versus GS 8

08

78.3%

77%

GS 9 versus GS 7

14

82.6%

80%

GS 8 versus GS 7

04

73.6%

64.6%

FTIR, Fourier Transform Infrared; GS, Gleason score; PLS-DA, partial least squares discriminant analysis.

and 1240 cm−1 are primarily due to the symmetric
and asymmetric stretching modes of phosphodiester groups respectively.53 As phosphodiester
groups are found in nucleic acids, these two bands
are associated with the nucleic acid content of a
cell.54 The increase in the bands at 1120 and
1170 cm−1 are associated with carbohydrates.
These bands were highly intense in plasma
from healthy donors compared with that from
cancer patients. The protein spectra (region
14

1300–1800 cm−1) were relatively weak in the
plasma from cancer patients compared with that
from healthy donors. The decreased protein content in the malignant condition suggests an
induced diversification of energy to meet high
energy demands during the malignant stress of
cell.55 A decreased protein content was also
observed in the FTIR spectra of serum from
patients with lung cancer compared with healthy
controls.56 The bands at 2800–3000 cm−1 and
journals.sagepub.com/home/tam
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Figure 13. Relative weightings of pure molecular reference species from least squares fit of Raman spectra of
plasma from healthy donors and prostate cancer patients with different Gleason scores.
Error bars represent the standard error.

1740–1750 cm−1 were reduced, representing the
depletion of lipids and fatty acids in the plasma
from prostate cancer patients. This may be
because of the decreased levels of triglycerides
and fat in the region of malignant tissue due to
the enhanced demand of energy in the development and progression of carcinoma.57 The mean
Raman and FTIR spectrum analysis showed
more intense bands related to proteins and lipids
in the plasma from healthy controls compared
with prostate cancer patients. An increase in the
bands associated with nucleic acids were observed
in the Raman spectra of plasma from prostate
cancer patients. Conversely, a decreased vibration of nucleic acids was observed in the FTIR
spectra of prostate cancer patients.
The same spectral features that discriminates the
Raman spectra of plasma from healthy control
and prostate cancer patients were also found to
discriminate Raman spectra of plasma from different GS prostate cancer patients. Increases in
nucleic acids were observed in prostate cancer of
different Gleason score compared with benign
prostatic hyperplasia.58 This study suggests that
the increase in DNA/RNA, plasma free amino
journals.sagepub.com/home/tam

acids such as tyrosine, tryptophan and decrease in
phenylalanine and β-carotene may plays a crucial
role in progression from low to high GS. Similarly,
the Raman spectral analysis of lymphocytes also
shows an increase in lipids, phospholipids and
nucleic acids and a decrease in β-carotene with an
increase in GS. The FTIR spectral analysis of
prostate cancer patients with different GS shows
an increase in the protein bands with an increase
in GS. This suggests a difference in the protein
content of the cancerous tissue with progression
to a more aggressive state. Differentiation based
on DNA, carbohydrates and lipid content has
already been proven useful in the discrimination
of benign from malignant breast disease.59 An
increase in these spectral features was observed as
the breast cancer progressed from benign to
malignant. In this study also, an increase in the
same spectral features was also observed with an
increase in GS. An increase in the protein (1300–
1700 cm−1) and lipid (2800–2963 cm−1) regions
of the spectra with an increase in GS has also
been reported previously.60
The PCA analysis performed on the Raman spectra of plasma from healthy control and prostate
15
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Figure 14. Relative weightings of pure molecular reference species from least squares fit of FTIR spectra of
healthy donors and different Gleason scores of prostate cancer plasma samples.
Error bars represent the standard error.

cancer patients, as well as on the Raman spectra
of plasma and lymphocytes from patients with
different GS showed no discrimination between
the analysed groups. However, some discrimination was observed between the spectra of lymphocytes from healthy donors and prostate cancer
patients. PC1 shows positive bands associated
with glycogen (484 cm−1), glycerol (630 cm−1),
lipids (1436 cm−1), DNA/RNA (1608 cm−1) and
amide I (1650 cm−1) and negative bands associated with proteins (618, 640, 755, 935, 1128 and
1206 cm−1), carbohydrates (1128, 1153 and
1343 cm−1), DNA/RNA (725, 785, 828, 1177,
1317, 1373, 1487 and 1510 cm−1), saccharides
(854 and 898 cm−1), phenylalanine (1001 and
1104 cm−1) and amide II (1544 cm−1). PC2 shows
positive bands related to proteins (618, 640, 754,
850 cm−1), DNA/RNA (722, 781, 826, 896,
1315, 1342, 1459, 1485 cm−1), phenylalanine
(1001 cm−1), lipids (1126, 1260 cm−1), amide I
(1673 cm−1), amide II (1260 cm−1) and saccharides (1370 cm−1) and negative bands related to
cholesterol (608 cm−1), glycerol (630 cm−1), lipids
and fatty acids (733, 1070 cm−1), DNA/RNA
(766, 1070, 1287, 1609 cm−1), amide III (1224 cm−1),
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amide II (1544 cm−1) proteins (1161, 1406, 1392,
1560, 1593 cm−1).
The PCA analysis performed on the second
derivative FTIR spectra of plasma from healthy
donors and prostate cancer patients, as well as on
the second derivative FTIR spectra of plasma
from patients with different GS showed good discrimination between the analysed groups. For
healthy donors versus prostate cancer patients, the
PC1 shows positive bands related to fatty acids,
triglycerides, cholesterol, lipids (1745, 2953,
2972, 2926, 2960 and 3011 cm−1) and negative
bands related to glycogen (1040 cm−1), DNA/
RNA (1088 and 1121cm−1) and proteins (1550,
1636, 1656, 3277 and 3294 cm−1). PC2 shows
positive bands related to glycogen (1040 cm−1),
DNA/RNA (1088 and 1121cm−1), fatty acids, triglycerides, cholesterol, lipids (1745, 2853, 2872,
2926, 2963 and 3013 cm−1), amide I (1634 cm−1)
and amide A (3277, 3294 cm−1) and negative
bands related to amide I (1537 cm−1) and amide
II (1636 cm−1). This analysis confirms the significant discriminating features between the two
groups belong to DNA/RNA, proteins and lipids.

journals.sagepub.com/home/tam

The PLS-DA model classified Raman spectra of
plasma from healthy donors and prostate cancer
patients with a sensitivity and specificity of
89.6% and 90%, respectively. The model classified plasma Raman spectra from patients with
different GS with a sensitivity and specificity
ranging from 67% to 80%. Similarly, the
PLS-DA classified Raman spectra of lymphocytes from healthy donors and prostate cancer
patients with a sensitivity and specificity of 92%
and 90%, respectively, and Raman spectra of
lymphocytes from patients with different GS
with a sensitivity and specificity ranging from
65% to 95%. The PLS-DA model classified
FTIR spectra of plasma from healthy donors and
prostate cancer patients with a sensitivity and
specificity of 99% and 98.4%, respectively, and
FTIR spectra of plasma from patients with different GS with a sensitivity and specificity ranging from 65% to 80%.
As mentioned earlier, the CLS fitting analysis
showed an increased weighting of uric acid, interleukin-6, phosphatidylethanolamine, creatinine
and RNA and a decreased weighting of albumin
and β-carotene in the Raman spectra of plasma
from prostate cancer patients compared with
the healthy donors (Figure 13). The increased
weighting of RNA and decreased weighting of
β-carotene in the plasma from prostate cancer
patients was discussed earlier. The weighting of
RNA was also increased with an increase in GS.
This suggests that an increase in RNA or micro
RNAs may be responsible for progression to high
GS. The elevated uric acid level was observed in
plasma from prostate cancer patients compared
with that from healthy donors and this increased
weighting was also found with an increase in GS.
Sangkop et al. reported that the increase in plasma
uric acid levels has an impact on prostate cancer
cell growth and suggested that lowering plasma
uric acid levels is likely to be therapeutically
beneficial.61
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Error bars represent the standard error.

For the GS study, PC1 shows positive bands
related to amide I (1636 and 1691 cm−1) and negative bands related to amide I (1656 cm−1) and
fatty acids, triglycerides and lipids (1745, 2873
and 2926 cm−1). PC2 shows positive bands related
to amide II (1542, 1560 cm−1), amide I (1650 cm−1)
and negative bands related to glycogen (1040 cm−1),
DNA/RNA (1088 and 1121cm−1), amide I
(1644 cm−1), amide II (1539 cm−1) fatty acids, triglycerides and lipids (1745, 2853 and 2926 cm−1).

Figure 15. Relative weightings of pure molecular reference species from least squares fit of Raman spectra of lymphocytes from healthy donors and prostate cancer
patients with different Gleason scores.
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The albumin weighting was found to be higher in
plasma from healthy donors compared with cancer patients.62 Previous studies have found low
serum albumin concentration in cancer patients
and also suggested serum albumin levels as a
prognostic marker for various cancers.63,64 The
weighting of plasma albumin was also found to
decrease with an increase in GS. Lower albumin
concentration, or hypoalbuminemia, is a rather
late phenomenon with cancer progression.62,65
Lower albumin levels in advanced cancer stages
are associated with an inflammatory response
with the release of interleukin-6, cytokines and
other factors.62 An increase in interleukin-6 levels was observed in the plasma from cancer
patients compared with that from healthy
donors.66 In our study, interleukin-6 levels were
found to increase with an increase in GS.
Interleukin-6 is a pro-inflammatory cytokine that
is expressed in prostate tumours and the stromal
tumour micro-environment.67 Baillargeon et al.
reported that increased serum and plasma interleukin-6 levels are associated with progression
and poor prognosis in prostate cancer patients.68
Serum interleukin-6 was found to be significantly
elevated in patients with GS > 6.69 Shariat et al.
observed that preoperative interleukin-6 levels
were elevated in patients with a final Gleason
sum of 7 or greater.70
An increased weighting of phosphatidyl-ethanolamine (P-ethanolamine) was observed in
plasma from cancer patients compared with
healthy donors. A lipidomic study by Zhou et al.
reported an increase in plasma phosphatidylethanolamine levels in prostate cancer patients
compared with healthy control subjects.71
Increased levels of plasma creatinine were found
in the cancer patients compared with healthy
donors. Weinstein et al. reported an increased
level of pre-diagnostic serum creatinine in prostate cancer patients compared with controls.72
However, serum creatinine concentrations can
also be influenced by various other factors such
as age, sex, muscle mass, diet, physical activity,
blood pressure, diseases such as diabetes, hypertension and heart disease.73,74
The CLS fitting analysis performed on the second
derivative FTIR spectra (Figure 14) of plasma
from healthy control and prostate cancer patients
with different GS showed increased levels of KGF
in the plasma from healthy donors compared with
that from cancer patients. KGF is a stromally
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derived, androgen dependent epithelial mitogen
that has been implicated in the regulation of cell
growth and differentiation in prostate tissue.
Higher concentrations of KGF have been found in
the serum of patients with benign prostatic hyperplasia compared with those with prostate cancer.75
Also, the experimental data here demonstrated
decreased levels of phosphatidyl-ethanolamine and
increased levels of phosphatidyl-inositol and phosphatidyl-serine were observed in the plasma samples from prostate cancer patients compared with
heathy donors. In addition, the weighting of
plasma ubiquitin was decreased in the prostate
cancer patients compared with heathy donors.
The CLS fitting analysis performed on the FTIR
spectra identified more pure components compared with the Raman spectra. A decreased
weighing of albumin and an increased weighing of
uric acid and interleukin-6 were observed in both
FTIR and Raman spectra of plasma from prostate cancer patients. An increased weighing of
p-ethanolamine was observed in the Raman spectra of plasma from cancer patients, whereas
decreased weighing of p-ethanolamine was
observed in the FTIR spectra of plasma from cancer patients. In addition, two more phospholipids, p-serine and p-inositol, were observed with
an increased weighting in the FTIR spectra of
prostate cancer patients. Similarly, an increased
weighing of KGF, triglyceride, interleukin-8 and
decreased weighing of ubiquitin were also
observed in the FTIR spectra of prostate cancer
patients. These pure components were not
observed in the CLS fitting analysis performed on
the Raman spectra of plasma from control and
cancer patients. A decreased weighing of βcarotene and increased weighing of creatine and
RNA which were seen in the Raman spectral
analysis was not observed in the FTIR spectral
analysis. The variations in the CLS fitting analysis results of FTIR and Raman spectra may be
due to the employment of different pre-processing and sample preparation methods. Second
derivative FTIR spectra and underivatized Raman
spectra were used in this analysis. The FTIR
spectra were recorded from diluted and dried
plasma samples whereas Raman spectra were
recorded from liquid plasma samples. The
changes in the sample preparation methods might
also affect the identification of plasma components. However, further studies are required to
investigate these variations due to the different
sample preparation methods.
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The CLS fitting analysis performed on the Raman
spectra of lymphocytes (Figure 15) showed an
increased weighing of actin, cholesterol, RNA,
interleukin-8, linoleic acid, prostaglandin E1,
PUFA and uric acid and decreased weighing of
β-carotene, tumour necrosis factor alpha (TNFα), histone (or histone 2A), glycogen and ubiquitin were observed in the lymphocyte spectra of
cancer patients compared with controls. The
decreased weighing of β-carotene and increased
weighing of RNA and uric acid were also observed
in the Raman spectra of patient plasma samples
(Figure 13). Similarly, an increased weighing of
interleukin-8 and a decreased weighing of ubiquitin were observed in the FTIR spectra of patient
plasma samples (Figure 14). The increased actin
in patient lymphocytes might be due to the accumulation of actin in the cell nucleus during cancer conditions.76 The increase in cholesterol in
cancer patients might be due to diet-induced
hypercholesterolemia. Moon et al. reported that
diet-induced hypercholesterolemia promoted
metastasis in orthotopic xenograft PC-3 cells (a
prostate cancer cell line) by increasing the expression of the metastasis-associated protein
IQGAP1.77 Recent studies also suggest a positive
relationship between hypercholesterolemia and
carcinogenesis in some cancers like breast and
prostate.78 TNF-α is an inflammatory cytokine
frequently found in the tumour microenvironment and a decreased weighing of TNF-α was
observed in the lymphocytes of prostate cancer
patients. A study by Zhao et al. reported that low
concentrations of TNF-α significantly enhanced
colon cancer cell migration and invasion by
upregulating TROP-2 via the ERK1/2 signalling
pathway.79 As mentioned earlier, a decreased
weighting of histone 2A was observed in the lymphocytes of prostate cancer patients and no
expression of histone 2A was observed in the lymphocytes from prostate cancer patients with GS 7
and GS 9. A study by Vieira-Silva et al. reported
the downregulation of histone 2A variants in
prostate cancer compared with normal prostate
tissue.80 The increased weighing of linoleic acid
and PUFA suggests an increase of polyunsaturated fatty acids although there is little evidence
of an association of polyunsaturated fatty acids
with risk of prostate cancer.81
It is acknowledged that a limitation of the present
study is that only a few age matched controls
were available for inclusion in the healthy donor
cohort. To investigate any age-related differences, PCA was performed on the age matched
journals.sagepub.com/home/tam

healthy controls (n = 5), non-age matched healthy
controls (n = 28) and prostate cancer plasma samples (n = 37). PCA showed overlapped clusters for
age and non-age matched controls (Online
Supplementary Figure S1). This suggests that the
differences observed between the control and
cancer patients are not related to age. Since PCA
is a tool for data visualization and trends, CLS
fitting analysis was also performed to confirm the
effect of age on identification of cancer analytes.
Similar differences were observed in the weighing
of plasma analytes between age and non-age
matched versus prostate cancer patients as
reported earlier. More interestingly, significant
differences were also observed between the age
matched controls versus cancer patients compared
with non-age matched controls versus cancer
patients (Online Supplementary Figure S2). This
confirms that these differences can be attributed
to the development of cancer. However, this
study must be validated on a larger number of age
matched controls to confirm these findings.
Conclusion
In this study, HT-Raman and HT-FTIR spectroscopy of blood plasma and Raman spectroscopy of lymphocytes along with machine learning
procedures were used to evaluate the spectral differences between plasma from healthy donors
and prostate cancer patients as well as between
prostate cancer patients with varying GS. The
Raman and FTIR mean spectral analysis of blood
plasma and lymphocytes exhibited consistent
changes related to proteins, lipids and nucleic
acids in plasma from healthy donors and prostate
cancer patients with varying GS. PCA demonstrated discrimination between the Raman and
FTIR spectra of plasma and lymphocytes from
healthy donors and prostate cancer patients. The
PLS-DA model classified Raman spectra of
plasma from healthy donors and prostate cancer
patients with a sensitivity and specificity of 89.6%
and 90%, respectively, and Raman spectra of
lymphocytes from healthy donors and prostate
cancer patients with a sensitivity and specificity of
92% and 90%, respectively. Similarly, the
PLS-DA model classified FTIR spectra of plasma
from healthy donors and prostate cancer patients
with a sensitivity and specificity of 99% and
98.4%, respectively. The model classified Raman
and FTIR plasma and lymphocytes spectra from
patients with varying GS with a sensitivity and
specificity ranging from 65% to 95%. The CLS
fitting analysis performed on the Raman and
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FTIR spectra of blood plasma and Raman spectra
of lymphocytes from healthy donors and prostate
cancer patients with different GS identified a
panel of analytes that may be involved in the
development and progression of prostate cancer.
The current study focused on the discrimination
of control and prostate cancer patients with different GS using vibrational spectroscopy of liquid
biopsies. However, most patients present with
low risk localised tumours and active surveillance
is usually recommended whereas aggressive treatment is required for patients with intermediate
and high-risk prostate cancer. Thus, further work
will be required to identify patients with clinically
significant prostate cancer from those with low
risk disease. Previous work on FTIR spectroscopy
of DNA from prostate tissues showed a cancer
DNA phenotype that could be used as a biomarker for cancer progression.82
In addition, validation of this exploratory study on
a larger cohort using age matched controls will be
necessary to evaluate the efficacy of HT-Raman
and HT-FTIR spectroscopy of liquid biopsies for
prostate cancer screening. Future work should
also involve biological assays showing proteins,
lipids, circulating nucleic acids and other analyte
levels to corroborate these findings. Biofluid based
vibrational spectroscopy is reagent free, label free,
cost effective, rapid and can be used to quantity
multiple analytes in a single measurement83 and
this study has shown that this technology may also
have potential for the translation of liquid biopsy
based diagnostics into the clinic.
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